Compare · HUM vs SERA
HUM vs SERA
Side-by-side comparison of Humana Inc. (HUM) and Sera Prognostics Inc. (SERA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and SERA operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $48.02B, about 598.2x SERA ($80.3M).
- SERA has been more active in the news (13 items in the past 4 weeks vs 6 for HUM).
- HUM has more recent analyst coverage (25 ratings vs 8 for SERA).
- Company
- Humana Inc.
- Sera Prognostics Inc.
- Price
- -
- -
- Market cap
- $48.02B
- $80.3M
- 1M return
- -
- +8.51%
- 1Y return
- -
- -30.61%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 13
- Recent ratings
- 25
- 8
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Sera Prognostics Inc.
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Latest HUM
- Humana upgraded by Wells Fargo with a new price target
- SEC Form 4 filed by Director Hilzinger Kurt J
- The Humana Foundation Deepens Investment in Emotional Health, Announcing Over $12 Million in New Grants
- SEC Form 11-K filed by Humana Inc.
- SEC Form 11-K filed by Humana Inc.
- Humana Inc. to Release Second Quarter 2026 Results on July 29, 2026
- Humana Awarded Statewide Illinois HealthChoice Medicaid Contract, Expanding Access to Care Across the State
- Humana Announces Agreement to Divest Minority Interest in Gentiva
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Humana completes $83 million Florida infrastructure investment to deepen coordinated patient care approach
Latest SERA
- Director Phillips Joshua was granted 24,686 shares, increasing direct ownership by 43% to 81,691 units (SEC Form 4)
- Director Mirza Mansoor Raza was granted 24,197 shares, increasing direct ownership by 42% to 81,937 units (SEC Form 4)
- Director Lawrence Sandra Aj was granted 24,702 shares, increasing direct ownership by 150% to 41,175 units (SEC Form 4)
- Director Kamdar Kim P. was granted 25,847 shares, increasing direct ownership by 79% to 58,420 units (SEC Form 4)
- Director Critchfield Gregory C was granted 24,020 shares, increasing direct ownership by 3% to 846,886 units (SEC Form 4)
- Director Capone Mark Christopher was granted 44,379 shares (SEC Form 4)
- Director Barlow Jane F was granted 24,375 shares, increasing direct ownership by 107% to 47,088 units (SEC Form 4)
- PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
- SEC Form 3 filed by new insider Capone Mark Christopher
- Sera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits